NASP Stresses the Need for Legislative Changes
In a recent gathering in Washington, the National Association of Specialty Pharmacy (NASP) expressed serious concerns about the legislation currently moving through Congress aimed at improving Medicare Part D access. While the intent is commendable, the potential implications on patient safety and pharmacy market dynamics raise significant red flags. The House Committee on Energy and Commerce has already passed the bill H.R. 2484, but NASP leaders emphasize that further revisions are essential to safeguard both patients and pharmacies.
Legislation Introduced with Key Concerns
During the committee's discussions, Representative Auchincloss highlighted critical issues surrounding Stark law protections. These laws exist to prevent physician self-referral, ensuring that patients receive unbiased care. The proposed bill could inadvertently allow for steering practices that benefit financially vested interests, ultimately compromising patient choice. Sheila Arquette, President and CEO of NASP, articulated these concerns, advocating for the need to preserve patient autonomy in selecting their pharmacies.
Understanding the Implications of the Legislation
Currently, physicians are allowed to dispense medications provided they meet specific state licensure requirements. However, the new legislation would permit physicians to distribute any Part D drug without necessitating an in-person consultation more than annually. This raises alarming issues regarding the fundamental pharmacist-patient relationship that is crucial in managing specialty medications.
Importance of Specialty Pharmacy Accreditation
One of the pillars of specialized pharmacy care is accreditation, which guarantees that pharmacies meet high standards in clinical care and drug management. The proposed changes would let any physician ship medications without adhering to these important accreditation standards. This shift could lead to a significant decline in the level of care that patients with complex health conditions receive, as physicians may not have the necessary infrastructure to provide adequate 24/7 support.
Collaborative Efforts for Effective Change
Despite opposition to the bill as it currently stands, the NASP is committed to working collaboratively with lawmakers to ensure the concerns about specialty pharmacy are effectively addressed. The association aims to support legislative efforts that truly prioritize patient safety and fair market competition in the pharmacy sector.
NASP's Role in Pharmacy Advocacy
NASP represents a diverse array of stakeholders within the specialty pharmacy community. This includes patients with complex conditions such as cancer and organ transplants. Through its advocacy, NASP ensures that these patients continue to receive the high-quality care they deserve from accredited specialty pharmacies, which guarantee proper drug management and patient support services.
Frequently Asked Questions
What is the main concern NASP has regarding the new legislation?
NASP is concerned that the legislation could undermine patient safety by allowing physician self-referral and potentially steering patients to certain pharmacies against their will.
How does the current legislation affect pharmacy market competition?
The legislation may reduce fair competition in the pharmacy market as it could incentivize directing patients to physician-owned pharmacies, undermining patient choice.
What standards do specialty pharmacies need to meet?
Specialty pharmacies must be accredited by recognized organizations to ensure they provide consistent quality in clinical care and drug management.
What initiatives is NASP proposing to address these concerns?
NASP is advocating for collaborative discussions with lawmakers to revise the legislation in a way that improves patient safety and maintains fair pharmacy competition.
How can stakeholders support NASP’s mission?
Stakeholders can raise awareness about the importance of maintaining high standards in specialty pharmacy care and support initiatives aimed at safeguarding patient rights.
